HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
The Dova study is for children below 18 years with primary Immune Thrombocytopenia (ITP) who have had an insufficient response to previous treatment.
Individuals with beta thalassemia that is treated with regular transfusions, and who are between the ages of 18 and 40 years old, may be able to participate.
ICON 3 is a prospective, open label, randomized, multi-center phase 3 clinical trial comparing eltrombopag with the enrolling physician’s choice of front line therapy.
Pioneering new approaches to diagnosis, care, and treatment for patients with red blood cell disorders with novel gene therapies and stem-cell-based treatments that aim to reduce symptoms and prolong life.